Latest Healthcare It News

4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.

Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.

SDI Limited’s acquisition by Beijing Guoci subsidiary is now effective following New South Wales Supreme Court approval, with the ASX suspension commencing and cash payout scheduled for early July.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.

Echo IQ has locked in a binding Heads of Agreement with Pro Medicus for a strategic A$20 million investment and a US commercial partnership to accelerate adoption of its AI-powered cardiac diagnostic platform.

The Supreme Court of New South Wales has approved the scheme of arrangement for SDI Limited’s acquisition by Beijing Guoci’s subsidiary, paving the way for a cash payout and ASX suspension.

Kingfish Limited posted a $13.6 million net loss for the year ended 31 March 2026, with portfolio returns lagging the benchmark amid geopolitical tensions and AI sector uncertainty.

Pathkey.AI has finalised its takeover of Chipforge, an AI-driven semiconductor design company, issuing shares and performance rights as consideration. The move broadens Pathkey's AI platform capabilities from clinical trials into semiconductor engineering, aiming to shorten chip development cycles significantly.

Vection Technologies has locked in approximately $2.3 million in new AI-related contracts spanning healthcare, luxury fashion, public services, airport passenger assistance, and security, pushing total orders since April 2026 to around $7 million.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Arena REIT's portfolio valuation rises by $11.5 million in H2 FY2026, underpinning a 5.5% increase in distributions and continued active portfolio management.